From apprentice to team leader: Nicole Wegscheidler's career shows how curiosity, resilience and growth can unlock unexpected ...

MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...

Q3 net sales grew +4% (cc ¹, +4% USD), with core operating income ¹ +10% (cc, +11% USD) Sales growth driven by priorit ...

Want to help lead the clinical development of potential new medicines? Here you can be part of running large clinical trials and steering the path to regulatory approval to treat patients around the ...

Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapies Novartis advances strategy of focused portfolio and prioritized therapeutic ...

Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference medicine Humira®* HCF formulation adalimumab offers ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Explore opportunities with Novartis below.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Proudly partnering India since 1947. Together with our people, reimagining what’s possible for patients, today and tomorrow by harnessing science and innovation India is amongst a handful of countries ...

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42. Although artificial intelligence has been ...